Abstract

Direct-acting antivirals have achieved high sustained virologic response (SVR) rates in the treatment of chronic hepatitis C virus (HCV) infection. However, data on retreatment strategies following failure of glecaprevir/pibrentasvir (G/P) therapy remain limited. We report the case of a 48-year-old man with genotype 3 chronic HCV infection who experienced virologic failure despite full adherence to an 8-week G/P regimen. The patient was subsequently treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks, resulting in normalization of liver enzyme levels and undetectable HCV ribonucleic acid at  the end of treatment and 12 weeks after treatment, confirming achievement of SVR12. This case demonstrates that SOF/VEL/VOX may represent an effective and safe salvage therapy for patients with genotype 3 HCV infection who fail prior G/P treatment and provides clinical insight to guide retreatment decisions.